Gene · 55869
Papers3,134
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
101 to 120 of 3,134
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Off-target binding of the histone deacetylase inhibitor vorinostat to carbonic anhydrase II and IX. | Acta Crystallogr F Struct Biol Commun | 2025 | 40856436 | PubTator, text mining | PubMed |
| The HDAC inhibitor romidepsin renders liver cancer vulnerable to RTK targeting and immunologically active. | Nat Commun | 2025 | 40855049 | PubTator, text mining | PubMed |
| ZDHHC12 Palmitoylates HDAC8 to Promote the Progression of Hepatocellular Carcinoma Associated with a Diet High in Saturated Fatty Acids. | Adv Sci (Weinh) | 2025 | 40787880 | PubTator, text mining | PubMed |
| RNA Epigenetics in Cancer: Current Knowledge and Therapeutic Implications. | MedComm (2020) | 2025 | 40761481 | PubTator, text mining | PubMed |
| The role of epigenetics in pulmonary fibrosis: recent advances in mechanistic insights and therapeutic implications. | Front Mol Biosci | 2025 | 40746422 | PubTator, text mining | PubMed |
| DGMM: A Deep Learning-Genetic Algorithm Framework for Efficient Lead Optimization in Drug Discovery. | J Chem Inf Model | 2025 | 40736165 | PubTator, text mining | PubMed |
| Integrating deep learning for post-translational modifications crosstalk on Hsp90 and drug binding. | J Biol Chem | 2025 | 40716748 | PubTator, text mining | PubMed |
| Assay2Mol: Large Language Model-based Drug Design Using BioAssay Context. | ArXiv | 2025 | 40709303 | PubTator, text mining | PubMed |
| In silico screening of a designed focused chemical space identifies novel alkyl hydrazides as potent HDAC11 inhibitors. | Comput Biol Med | 2025 | 40617084 | PubTator, text mining | PubMed |
| A comprehensive review of histone modifications during mammalian oogenesis and early embryo development. | Histochem Cell Biol | 2025 | 40580240 | PubTator, text mining | PubMed |
| Recent progress in synthetic strategies to develop potent, HDAC8-selective, small-molecule inhibitors. | Bioorg Med Chem Lett | 2025 | 40541580 | PubTator, text mining | PubMed |
| Histone modifications and metabolic reprogramming in tumor-associated macrophages: a potential target of tumor immunotherapy. | Front Immunol | 2025 | 40375990 | PubTator, text mining | PubMed |
| Exploring the potential of Gonolobus condurango as a histone deacetylase inhibitor in triple-negative breast cancer cell lines: in vitro study. | BMC Complement Med Ther | 2025 | 40375313 | PubTator, text mining | PubMed |
| Discovery of a potential hematologic malignancies therapy: Selective and potent HDAC7 PROTAC degrader targeting non-enzymatic function. | Acta Pharm Sin B | 2025 | 40370550 | PubTator, text mining | PubMed |
| Augmenting the Anti-Leukemic Activity of the BCL-2 Inhibitor Venetoclax Through Its Transformation Into Polypharmacologic Dual BCL-2/HDAC1 and Dual BCL-2/HDAC6 Inhibitors. | Drug Dev Res | 2025 | 40370107 | PubTator, text mining | PubMed |
| Synergistic HDAC4/8 Inhibition Sensitizes Osteosarcoma to Doxorubicin via pAKT/RUNX2 Pathway Modulation. | Int J Mol Sci | 2025 | 40332124 | PubTator, text mining | PubMed |
| Mechanistic Underpinnings of Epigenetic Enzyme-Responsive Nanoparticles. | ACS Appl Bio Mater | 2025 | 40307668 | PubTator, text mining | PubMed |
| A review of machine learning methods for imbalanced data challenges in chemistry. | Chem Sci | 2025 | 40271022 | PubTator, text mining | PubMed |
| Conversion of Ku80 K568 crotonylation to SUMOylation facilitates DNA non-homologous end joining and cancer radioresistance. | Signal Transduct Target Ther | 2025 | 40254688 | PubTator, text mining | PubMed |
| Epigenetics of maternal-fetal interface immune microenvironment and placental related pregnancy complications. | Front Immunol | 2025 | 40248704 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/55869/papers?page=6